Next Financial Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Next Financial Group’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-52	Closed	-$8K	–	2381
2019 Q3	$8K	Buy	+52	New	+$9.06K	﹤0.01%	1761
2017 Q4	–	Sell	-1	Closed	–	–	475
2017 Q3	$0	Hold	1	–	–	﹤0.01%	1777
2017 Q2	$0	Buy	+1	New	+$196	﹤0.01%	1913

Other funds holding CRBP

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Next Financial Group's CRBP Position: Q4 2019 in Review

Next Financial Group sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 52 shares — an estimated $8K sold.

Next Financial Group first reported a position in CRBP in Q2 2017 and held it in 3 quarters. The position peaked at $8K in Q3 2019. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

Next Financial Group reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Next Financial Group sold 52 Corbus Pharmaceuticals shares in Q4 2019, an estimated $8K.
Next Financial Group first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 3 quarters.
Next Financial Group's Corbus Pharmaceuticals position peaked at $8K in Q3 2019.
105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on Next Financial Group's 13F filing for Q4 2019, filed 21 Jan 2020.